Pharmaceutical Supply, Pharmaceutical Manufacturing, Contract …
Women in STEM: Gitte Barknowitz’s journey to leading global initiatives Jane Koo on leading regulatory affairs at CTMC: A journey from mAbs to cellular therapies Women in Science - engineering life’s mysteries: Joaquima Guix Salichs’ journey Women in science - Alison O'Neill at YPrime on thinking out loud and collaborating Vaxess' Rachel Sha - 'own the seat at the table that you have and ...
SANOFI - CEPiA
CEPiA (Commercial & External Partnership, Industrial Affairs) is an organization fully dedicated to third party activities within the Industrial Affairs of Sanofi.One of the key activities of CEPiA is to offer a broad range of innovative solutions including:Supply of Active Pharmaceutical Ingredients (APIs) and IntermediatesCustom Synthesis & API Contract ManufacturingPharma Contract ...
$680M deal with CBC and Mubadala shifts UCB's strategy
Aug 29, 2024 · The $680 million transaction, announced on August 26, involves the sale of established brands such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, along with UCB's Zhuhai manufacturing site, to CBC Group and Mubadala Investment Company.
Extractables and leachables analysis of pharmaceutical products
Feb 29, 2024 · A crucial undertaking when releasing pharmaceutical products for the market, is to determine the purity of the final product, necessitating the need to determine its impurity profile. Traditionally, this was concerned only with those impurities arising from the manufacture and degradation of the pharmaceutical product. Nowadays, migration of mobile chemical species from components used in the ...
F2G raises $100M to advance olorofim after FDA rejection
Sep 17, 2024 · One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.
Mid-size CRO market update - outsourcing-pharma.com
Sep 6, 2017 · The larger CROs have definitely taken notice of the opportunity, below is INC Research’s reported revenue by customer segment. You can see that small/mid-size biopharma now make up 47% (up from 41%) of INC Research’s total revenue base.
Rusan Pharma’s Ankleshwar facility gains US FDA GMP approval
Jul 23, 2024 · Rusan Pharma Private Limited has announced that its active pharmaceutical ingredient (API) manufacturing facility in Ankleshwar, Gujarat, has been granted Good Manufacturing Practice (GMP) approval by the FDA.
German pharma to submit FDA application after nerandomilast …
Sep 17, 2024 · Boehringer Ingelheim reported this week that its phase 3 Fibroneer-IPF trial had met its primary endpoint of an improvement in Forced Vital Capacity (FVC), a measure of lung capacity, versus placebo. “This is the first idiopathic pulmonary fibrosis phase-3-trial in a decade to meet its primary endpoint,” said Ioannis Sapountzis, Head of Global Therapeutic Areas at Boehringer Ingelheim, in ...
Nura Bio secures $140M to advance lead drug to next trials
Sep 19, 2024 · Nura Bio has announced the addition of $68 million to its series A financing, closing the round with a total of $140 million. The investment was led by The Column Group and joined by Samsara Bio Capital, Euclidean Capital and Sanofi Ventures.
AstraZeneca sells Losec and six more brands
Oct 1, 2019 · Cheplapharm Arzneimittel, a German pharmaceutical company, has agreed to purchase AstraZeneca’s commercial rights to Losec (omeprazole) and six other brands containing omeprazole, including Acimax, Antra, Mepral, Mopral, Omepral and Zoltum.